BERKELEY, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006.
The announcement will be followed by a live webcast at 1:30 p.m. PT / 4:30 p.m. ET of a discussion by Dynavax Technologies management of third quarter 2006 financial results.
The webcast can be accessed on Dynavax Technologies' website at http://www.dynavax.com under the Investors tab; at www.earnings.com; or via Thomson StreetEvents (www.streetevents.com), a password-protected site.
A telephonic replay will be available through November 2, 2006 by dialing 888-286-8010, access code: 6161 2023. International callers can dial +1-617-801-6888, access code: 6161 2023.
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine in Phase 3; and a therapy for non-Hodgkins lymphoma in Phase 2. Its preclinical asthma and COPD programs are partnered with AstraZeneca. Funding for the company's other preclinical programs in cancer, hepatitis B and hepatitis C therapies, and for an influenza vaccine has been provided by Symphony Dynamo, Inc. and NIH, but these programs represent future partnering opportunities. For more information, please visit www.dynavax.com.
SOURCE Dynavax Technologies Corporation
CONTACT: Shari Annes, Corporate Communications of Dynavax Technologies
Corporation, +1-650-888-0902, or email@example.com